https://www.selleckchem.com/pr....oducts/bms-986278.ht
Thus, hTBK1-c.978TA mutation may serve as a possible target for the treatment of ALS. A mutation may serve as a possible target for the treatment of ALS.Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC); however, its utility is hampered by the development of chemoresistance. This study aimed to investigate the synergistic role of WZ4003, a novel (nua) kinase (NUAK) inhibitor, in enhancing gefitinib sensitivity in NSCLC cells.
Like
Comment
Share
